Skip to main content

Table 2 Adverse events reported in the study

From: Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial

Event

Placebo

Ivermectin

p value

Heartburn

1

0

0.652

Anxiety

0

1

0.348

Cystitis

0

1

0.348

Nasal congestion

2

0

0.201

Back pain

1

0

0.652

Encephalitis

0

1

0.348

Peptic acid disease

1

0

0.652

Exanthema

0

1

0.348

Pharyngitis

1

0

0.652

Gastritis

1

1

0.844

Acute gastritis

1

0

0.652

Hyperglycaemia

1

0

0.652

Arterial hypertension

1

1

0.844

Urinary tract infection

0

2

0.094

Leucocytosis

1

0

0.652

Elevated lipase

1

0

0.652

Low back pain

1

0

0.652

Dizziness

1

0

0.652

Nausea

1

2

0.713

Pneumonia

1

0

0.652

Right ear otitis

1

0

0.652

Maculopapular pruritus

0

1

0.348

Skin rash

1

0

0.652

Gastroesophageal reflux

1

0

0.652

Heat rash

1

0

0.652

Tachycardia

1

0

0.348

Vertigo

0

1

0.348

  1. Values in frequency. Pearson χ2 test